Lupin Limited, a global pharmaceutical company, has announced the release of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, as a generic equivalent to Sunovion Pharmaceuticals, Inc.’s Latuda Tablets. Lupin reported this to the Bombay Stock Exchange. It issued a press release alerting the public to the situation. In the United States, the generic equivalent of Latuda tablets has been released. According to the press release, Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg (RLD Latuda) had an estimated annual sales of $4.2 billion in the United States.
The filing complies with the requirements of Regulation 30 of the Securities and Exchange Board of India (SEBI). The company’s headquarters are in Mumbai, India. It operates in the United States, India, South Africa, and throughout Asia Pacific, among other places.